Iveric Bio (ISEE) Named Best 2022 Idea at Cowen

Cowen analyst Ken Cacciatore reiterated an Outperform rating and $25.00 price target on Iveric Bio (NASDAQ: ISEE) and named it a Best Idea for 2022, saying it is de-risked and appears "substantially" undervalued.

The analyst commented, "Zimura's second pivotal GATHER2 GA trial is progressing, with results on track for H2:22. Our clinician discussions continue to reinforce our belief that this is well in excess of a $1B+ opportunity, and competitor Apellis' results have meaningfully de-risked the clinical development. In addition, we believe Zimura's safety profile looks superior & could prove a distinct commercial advantage. Add."

For an analyst ratings summary and ratings history on Iveric Bio click here. For more ratings news on Iveric Bio click here.

Shares of Iveric Bio closed at $14.79 yesterday.

You May Also Be Interested In

• McCormick & Company (MKC) PT Lowered to $60 at TD Cowen
• Freedom Broker Starts AngloGold Ashanti (AU) at Buy
• Moderna (MRNA) PT Raised to $77 at Piper Sandler